All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship.

نقش ارسنیک در القای آپوپتوزیس از مسیر Fas در بیماران لوسمی حاد پرومیلوسیتی با جابه‌جایی کروموزومی

Acute promyelocytic leukemia (APL) is a sub-type of acute myelogenous leukemia (AML) which occurs in about 10-15% of patients with AML. Approximately 20-30% of these patients, who are treated with the current standard All trans retinoic Acid(ATRA) and anthracyclines-based chemotherapy regimen, suffer relapse in less than a year. Arsenic trioxide (ATO), as a single agent, can induce ...

Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia

Acute promyelocytic leukemia (APL) is a hematological malignancy driven by a chimeric oncoprotein containing the C terminus of the retinoic acid receptor-a (RARa) fused to an N-terminal partner, most commonly promyelocytic leukemia protein (PML). Mechanistically, PML-RARa acts as a transcriptional repressor of RARa and non-RARa target genes and antagonizes the formation and function of PML nucl...

THE RELATIONSHIP BETWEEN THE LEVELS OF GRANULOCYTE-COLONY STIMULATING FACTOR AND LEUKOCYTOSIS INDUCED BY ALL-TRANS RETINOIC ACID IN ACUTE PROMYELOCYTIC LEUKEMIA Wu Wen. Division of Haematology/Oncology and Bone Marrow Transplant Unit,UDM,QMH Differentiation therapy with all-trans retinoic acid

Molecular basis for the diagnosis and treatment of acute promyelocytic leukemia

Acute promyelocytic leukemia is characterized by gene rearrangements that always involve the retinoic acid receptor alpha on chromosome 15. In the majority of patients t(15;17) is detected, which generates the promyelocytic leukemia gene/retinoic acid receptor alpha rearrangement. This rearrangement interacts with several proteins, including the native promyelocytic leukemia gene, thus causing ...

Use of All-Trans Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia

Twenty-four patients with acute promyelocytic leukemia (API) were treated with all-trans retinoic acid (45 to 100 mg/m2/day). Of these. eight cases had been either nonresponsive or resistant to previous chemotherapy; the other 1 6 cases were previously untreated. All patients attained complete remission without developing bone marrow hypoplasia. Bone marrow suspension cultures were studied in 1...